Buy Rating for Moleculin Biotech: Promising Progress with WP1066 in Pediatric Brain Tumors

In a report released today, Sara Nik from H.C. Wainwright reiterated a Buy rating on Moleculin Biotech, with a price target of $22.00.Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential Sara Nik has given her Buy rating due to a combination of factors related to Moleculin Biotech’s recent progress with WP1066. The Phase 1 clinical study, conducted in partnership with Emory University, demonstrated a clean safety profile and confirmed on-target inhibition of p-STAT3, which is crucial for its immune-modulatory and anti-tumor effects. Positive outcomes in pediatric patients, including partial tumor reduction and extended progression-free survival, underline the therapeutic potential of WP1066, particularly when explored in combination treatment strategies. Sara Nik also views the results as a significant step towards broadening Moleculin’s pipeline beyond annamycin while de-risking WP1066 as a viable candidate for further development. Although monotherapy effects were modest, this aligns with expectations for immune-modulating agents used in advanced refractory brain tumors. The findings suggest that WP1066 could serve as a foundational immune-priming therapy in future studies, reinforcing confidence in Moleculin’s innovative approach to addressing challenging pediatric brain tumors. Nik covers the Healthcare sector, focusing on stocks such as Cidara Therapeutics, Moleculin Biotech, and Cantargia AB. According to TipRanks, Nik has an average return of 47.4% and a 40.91% success rate on recommended stocks. In another report released yesterday, Roth MKM also initiated coverage with a Buy rating on the stock with a $31.00 price target.